- Home
- HWH vs ACXP Comparison
HWH vs ACXP Comparison
Compare HWH & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWH
- ACXP
- Stock Information
- Founded
- HWH 2021
- ACXP 2017
- Country
- HWH United States
- ACXP United States
- Employees
- HWH N/A
- ACXP N/A
- Industry
- HWH Other Pharmaceuticals
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- HWH Health Care
- ACXP Health Care
- Exchange
- HWH Nasdaq
- ACXP Nasdaq
- Market Cap
- HWH 8.1M
- ACXP 8.4M
- IPO Year
- HWH N/A
- ACXP 2021
- Fundamental
- Price
- HWH $1.33
- ACXP $0.43
- Analyst Decision
- HWH
- ACXP Strong Buy
- Analyst Count
- HWH 0
- ACXP 2
- Target Price
- HWH N/A
- ACXP $10.00
- AVG Volume (30 Days)
- HWH 58.4K
- ACXP 18.4M
- Earning Date
- HWH 08-11-2025
- ACXP 08-08-2025
- Dividend Yield
- HWH N/A
- ACXP N/A
- EPS Growth
- HWH N/A
- ACXP N/A
- EPS
- HWH N/A
- ACXP N/A
- Revenue
- HWH $1,262,664.00
- ACXP N/A
- Revenue This Year
- HWH N/A
- ACXP N/A
- Revenue Next Year
- HWH N/A
- ACXP N/A
- P/E Ratio
- HWH N/A
- ACXP N/A
- Revenue Growth
- HWH 37.84
- ACXP N/A
- 52 Week Low
- HWH $0.90
- ACXP $0.30
- 52 Week High
- HWH $7.20
- ACXP $3.33
- Technical
- Relative Strength Index (RSI)
- HWH 52.31
- ACXP 47.99
- Support Level
- HWH $1.15
- ACXP $0.52
- Resistance Level
- HWH $1.26
- ACXP $0.63
- Average True Range (ATR)
- HWH 0.10
- ACXP 0.09
- MACD
- HWH -0.01
- ACXP 0.00
- Stochastic Oscillator
- HWH 53.33
- ACXP 17.33
About HWH HWH International Inc.
HWH International Inc is and its consolidated subsidiaries operate a food and beverage business in Singapore and South Korea. The F&B business operates four cafes, two of which are located in South Korea and two in Singapore, as well as an online healthy food store, serving customers in Singapore.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.